Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
about
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual MeetingEfficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Best practices of ASRM and ESHRE: a journey through reproductive medicine.A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.Bulky pulmonary mucosa-associated lymphoid tissue lymphoma treated with yttrium-90 ibritumomab tiuxetan.Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma.Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.
P2860
Q27693252-DE0DA13F-6EDC-46E6-902F-204E03B21424Q28390181-A23C91F7-2A9C-410F-882C-849328C93F01Q33402171-90D6DA1D-FE2A-48CA-841E-90565EED21BCQ35956862-83728AB0-9404-4BAA-8220-1F35D7F27538Q37948748-05E54EE6-B1FA-4547-B36E-07DE453BAD7EQ38055459-9A104342-BCB9-4EAA-91E7-BD154EED8CAAQ41418657-8908CE38-2FCD-4BBC-B4BF-F37371B0A167Q41962813-3A9D1954-553E-4673-BC34-E9AD5E16F5C4Q45332759-74194976-9C33-40CE-806A-CE96E57E0B25Q50187344-8BBAB749-2C0D-444E-97BC-A64B61A30560Q53059192-C7B0AAD1-3139-4B59-BF77-D112887E8BE3
P2860
Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@en
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@nl
type
label
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@en
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@nl
prefLabel
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@en
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@nl
P2093
P1433
P1476
Japanese phase II study of 90Y ...... tory indolent B-cell lymphoma.
@en
P2093
Hirokazu Okumura
Keigo Endo
Kenichi Ishizawa
Kensei Tobinai
Kuniaki Itoh
Masafumi Taniwaki
Masaki Hayashi
Masaki Matsusako
Michinori Ogura
Norifumi Tsukamoto
P304
P356
10.1111/J.1349-7006.2008.00999.X
P577
2008-10-24T00:00:00Z